DIX HILLS, N.Y., Dec. 10, 2014 /PRNewswire/ -- ALTuCELL®, a cell-based biotechnology company, is bringing to market 25 years of sound medical research showing a reversal of type 1 diabetes in animal models with its registered ALTSuLIN® product. The advantage of ALTuCELL's patented non-invasive encapsulation technology is to infuse porcine-derived Sertoli cells without requiring immunosuppressant drugs. The use of this patented Sertoli cell process has been developed by ALTuCELL under the auspices of Riccardo Calafiore, MD at the University of Perugia. This exclusive technology is being fast tracked for a human pilot study overseas opening an opportunity for investor partners.
Millions of people are living with insulin dependent diabetes. Each year 15,000 children are diagnosed with type 1 diabetes, one of the most frequent chronic childhood diseases. "My mission is to cure, not control type 1 diabetes through ALTuCELL's proprietary technology that I would not hesitate to treat my own child living with this chronic condition," states Gary Harlem, founder and CEO, ALTuCELL. "I have committed significant personal resources to advance the science of our two patents to this stage, and we are seeking partners to help fund ALTSuLIN's proof of principle in humans," added Harlem.
Type 1 (or insulin-dependent) diabetes is an autoimmune disease that results in the destruction of the insulin-secreting beta cells in the pancreas. This lack of insulin results in elevated blood sugar (hyperglycemia). Currently, insulin therapy is the only approved available treatment for type 1 diabetes. Blood sugar control is critical for the prevention of potential secondary diabetes complications. Healthcare costs of type 1 diabetes in the U.S. alone are $14.9 billion each year, while all types of diabetes combined account for $245 billion in annual costs.
ALTuCELL is a private biotech company with a mission to bring to market a cure for people living with insulin-dependent diabetes and other neuro-generative conditions through its dual patented technologies ALTSuLIN and ALGINATE. ALGINATE is its patented non-invasive encapsulation technology. For more information visit: http://www.altucell.net/index.html.
CONTACT:Cori Lichter
ch@altucell.com
631-586-4940
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/altsulin-advanced-therapy-on-track-to-remediate-type-1-diabetes-in-millions-300007470.html
SOURCE ALTuCELL
